Literature DB >> 22934787

Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus.

Chirag G Patel1, Ken Ogasawara, Fatemeh Akhlaghi.   

Abstract

1. The purpose of this study was to investigate the contribution of MRP2 to the efflux of mycophenolic acid (MPA), and its phenyl glucuronide (MPAG) and acyl glucuronide (AcMPAG) metabolites, using Madin-Darby canine kidney II cells stably transfected with human MRP2 gene (MDCKII/MRP2 cells). 2. Compared to parental MDCKII cells, MPAG was significantly translocated from basolateral (BL) to apical (AP) side in MDCKII/MRP2 cells, indicating MPAG is a substrate for MRP2. AcMPAG is highly translocated from BL to AP side in both cells, suggesting that AcMPAG is actively secreted possibly through an efflux transporter other than MRP2. Appreciable translocation of MPA was not observed in MDCKII/MRP2 cells. 3. Furthermore, using MRP2-expressing Sf9 membrane vesicles, the Michaelis-Menten constant (Km) value for MRP2-mediated MPAG transport was calculated at 224.2 ± 42.7 µM. In the vesicle system, cyclosporine, tacrolimus and sirolimus did not inhibit the uptake of MPAG via MRP2. 4. These findings indicate that only MPAG not MPA and AcMPAG is a substrate for MRP2 and that the interaction between MPAG and concomitantly administered immunosuppressive agents does not occur at MRP2 level.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22934787      PMCID: PMC4116557          DOI: 10.3109/00498254.2012.713531

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  27 in total

Review 1.  A possible mechanism of gastrointestinal toxicity posed by mycophenolic acid.

Authors:  Michael F Neerman; Dawn M Boothe
Journal:  Pharmacol Res       Date:  2003-06       Impact factor: 7.658

Review 2.  Immunosuppressive drugs for kidney transplantation.

Authors:  Philip F Halloran
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

3.  In vitro study of mycophenolic acid glucuronidation.

Authors:  Nicolas Picard; Pierre Marquet
Journal:  Drug Metab Dispos       Date:  2004-12       Impact factor: 3.922

4.  Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2.

Authors:  Dennis A Hesselink; Reinier M van Hest; Ron A A Mathot; Fred Bonthuis; Willem Weimar; Ron W F de Bruin; Teun van Gelder
Journal:  Am J Transplant       Date:  2005-05       Impact factor: 8.086

Review 5.  Therapeutic monitoring of mycophenolic acid. A consensus panel report.

Authors:  L M Shaw; A Nicholls; M Hale; V W Armstrong; M Oellerich; R Yatscoff; R E Morris; D W Holt; R Venkataramanan; J Haley; P Halloran; R Ettenger; P Keown; R G Morris
Journal:  Clin Biochem       Date:  1998-07       Impact factor: 3.281

6.  Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.

Authors:  Nuria Lloberas; Juan Torras; Josep Ma Cruzado; Franc Andreu; Federico Oppenheimer; Jaime Sánchez-Plumed; Miguel Ángel Gentil; Mercé Brunet; Henrik Ekberg; Josep M Grinyó
Journal:  Nephrol Dial Transplant       Date:  2011-03-22       Impact factor: 5.992

7.  Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients.

Authors:  Maria Shipkova; Victor W Armstrong; Lutz Weber; Paul D Niedmann; Eberhard Wieland; Jane Haley; Burkhard Tönshoff; Michael Oellerich
Journal:  Ther Drug Monit       Date:  2002-06       Impact factor: 3.681

8.  Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA.

Authors:  R Evers; M Kool; L van Deemter; H Janssen; J Calafat; L C Oomen; C C Paulusma; R P Oude Elferink; F Baas; A H Schinkel; P Borst
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

9.  Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats.

Authors:  Mikako Kobayashi; Hiroshi Saitoh; Michiya Kobayashi; Koji Tadano; Yasushi Takahashi; Tetsuo Hirano
Journal:  J Pharmacol Exp Ther       Date:  2004-02-20       Impact factor: 4.030

10.  Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil.

Authors:  D R J Kuypers; Y Vanrenterghem; J P Squifflet; M Mourad; D Abramowicz; M Oellerich; V Armstrong; M Shipkova; J Daems
Journal:  Ther Drug Monit       Date:  2003-10       Impact factor: 3.681

View more
  12 in total

Review 1.  Sex differences in transplantation.

Authors:  Jeremiah D Momper; Michael L Misel; Dianne B McKay
Journal:  Transplant Rev (Orlando)       Date:  2017-02-20       Impact factor: 3.943

2.  Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients.

Authors:  Jean-Baptiste Woillard; Nicolas Picard; Antoine Thierry; Guy Touchard; Pierre Marquet
Journal:  Pharmacogenet Genomics       Date:  2014-05       Impact factor: 2.089

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

Authors:  Jin Zhou; Upendra A Argikar; John O Miners
Journal:  Methods Mol Biol       Date:  2021

5.  Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant.

Authors:  Calvin J Meaney; Patcharaporn Sudchada; Joseph D Consiglio; Gregory E Wilding; Louise M Cooper; Rocco C Venuto; Kathleen M Tornatore
Journal:  J Clin Pharmacol       Date:  2019-05-06       Impact factor: 3.126

6.  Meta-analysis of the associations of IMPDH and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking mycophenolic acid.

Authors:  Lin Cheng; Pu Yao; Bangbi Weng; Ming Yang; Qian Wang
Journal:  Eur J Clin Pharmacol       Date:  2022-05-07       Impact factor: 3.064

7.  Challenges and Opportunities with Predicting in Vivo Phase II Metabolism via Glucuronidation from in Vitro Data.

Authors:  Shufan Ge; Yifan Tu; Ming Hu
Journal:  Curr Pharmacol Rep       Date:  2016-11-08

8.  Transporter-Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate.

Authors:  Izna Ali; Jason R Slizgi; Josh D Kaullen; Marija Ivanovic; Mikko Niemi; Paul W Stewart; Alfred S Barritt; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2017-12-22       Impact factor: 6.875

9.  Association of ABCC2 Haplotypes to Mycophenolic Acid Pharmacokinetics in Stable Kidney Transplant Recipients.

Authors:  Daniel Brazeau; Calvin J Meaney; Joseph D Consiglio; Gregory E Wilding; Louise M Cooper; Rocco C Venuto; Kathleen M Tornatore
Journal:  J Clin Pharmacol       Date:  2021-07-20       Impact factor: 2.860

10.  A pilot study of leukocyte expression patterns for drug metabolizing enzyme and transporter transcripts in autoimmune glomerulonephritis.

Authors:  Melanie S Joy; Brittney V Roberts; Jinzhao Wang; Yichun Hu; Susan L Hogan; Ronald J Falk
Journal:  Int J Clin Pharmacol Ther       Date:  2014-04       Impact factor: 1.366

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.